Choroidal Vascularity Index as a Biomarker for Visual Response to Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema.
Choroidal Vascularity Index as a Biomarker for Visual Response to Antivascular Endothelial Growth Factor Treatment in Diabetic Macular Edema.
复制标题
DOI：
10.1155/2021/3033219
复制
发表时间：
2021
影响因子：
4.3
通讯作者：
Liang X
中科院分区：
文献类型：
--
作者：
Dou N;Yu S;Tsui CK;Yang B;Lin J;Lu X;Xu Y;Wu B;Zhao J;Liang X
探讨脉络膜血管指数（CVI）作为抗血管内皮生长因子（VEGF）治疗糖尿病性黄斑水肿（DME）视力疗效的预后因素。 我们回顾性分析了92只接受抗VEGF治疗的DME眼，将其分为应答者（获得≥ 5个字母）和无应答者（获得或丢失<5个字母）。对两组患者的基线系统特征和光学相干断层扫描特征进行评价，包括CVI、调整后的椭圆体区（EZ）反射率、视网膜下液（SRF）和视网膜内层（DRIL）紊乱。 无应答者的基线CVI显著低于应答者（0.66 ± 0.05、0.69 ± 0.05和0.72 ± 0.05，p = 0.014）。在调整其他因素后，基线CVI，DRIL，SRF和调整后的EZ反射率与视力结果显著相关（CVI：比值比（OR）= 0.17，p = 0.006;调整后的EZ反射率：OR = 0.56，p = 0.007; DRIL：OR = 6.71，p = 0.001; SRF：OR = 0.29，p = 0.008）。 基线时具有较高CVI、较高调整EZ反射率、存在SRF和不存在DRIL的DME患者在抗VEGF治疗后更可能获得> 5个字母的视力。CVI可能作为一种新的生物标志物的视觉反应，抗VEGF治疗DME。
To investigate the choroidal vascularity index (CVI) as a prognostic factor for the visual efficacy of antivascular endothelial growth factor (VEGF) treatment in diabetic macular edema (DME). We retrospectively reviewed 92 DME eyes receiving anti-VEGF treatment, which were stratified as responders (≥5 letters gained) and nonresponders (<5 letters gained or lost). Baseline systematic features and optical coherence tomography features, including the CVI, adjusted ellipsoid zone (EZ) reflectivity, subretinal fluid (SRF), and disorganization of the retinal inner layers (DRIL), were evaluated between the two groups. The baseline CVI was significantly lower in nonresponders than in responders (0.66 ± 0.05, 0.69 ± 0.05, and 0.72 ± 0.05, p = 0.014). After adjusting for other factors, the baseline CVI, DRIL, SRF, and adjusted EZ reflectivity were significantly associated with visual outcomes (CVI: odds ratio (OR) = 0.17, p = 0.006; adjusted EZ reflectivity: OR = 0.56, p = 0.007; DRIL: OR = 6.71, p = 0.001; and SRF: OR = 0.29, p = 0.008). DME patients with a higher CVI, higher adjusted EZ reflectivity, the presence of SRF, and the absence of DRIL at baseline were more likely to gain >5 letters in visual acuity after anti-VEGF treatment. CVI may serve as a novel biomarker for visual response to anti-VEGF treatment in DME.